Vividion is a next generation biotechnology company focused on expanding the therapeutic potential of small molecules. Drug development technology platform for a broad array of protein targets that have heretofore been deemed ‘undruggable’. CHP III is founding investor. August 2021 – acquired by Bayer AG for $2 billion.